COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-driven Monoclonal Antibody Program During the Omicron Surge
Willa Cochran(Johns Hopkins Hospital), Robin K. Avery(Johns Hopkins University), Dillon Goddard(Johns Hopkins Hospital), Dorry L. Segev(New York University), Debra Carter(Johns Hopkins Hospital), Daniel C. Brennan(Johns Hopkins University), William A. Werbel(Johns Hopkins University), Julie Langlee(Johns Hopkins Hospital), Sonsoles Salto‐Alejandre(Instituto de Biomedicina de Sevilla), Jaclyn Bannon(Johns Hopkins Hospital), Pali D. Shah(Johns Hopkins University), Kristin Freed(Johns Hopkins Hospital), Lindsay Barker(Johns Hopkins Hospital), Heba H. Mostafa(Johns Hopkins University)
Cited by 25
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation
|American Journal of Respiratory and Critical Care Medicine|2013|686